FindTrial
Sign In

Inj.histaglobulin in chronic urticaria.

The prospective study of efficacy of inj. Histaglobulin in treatment of Autologus Serum Skin Test (ASST) positive chronic idiopathic urticaria.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/026216
Enrollment
40
Registered
2020-06-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L501- Idiopathic urticaria

Interventions

Intervention1: Injection Histaglob: Dose- 1ml Rout- Subcutaneously Frequency of dose- once a week Duration- for 8 weeks Control Intervention1: Not applicable: Not applicable

Sponsors

Dr Nipun Kesarkar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patient who have history of daily or almost daily occurence of wide spread itching, spontaneous wheals for period of 6 weeks or more and who have autologus serum skin test positive.

Exclusion criteria

Exclusion criteria: 1 patient on long term immunosuppressants. 2 patient who had recent vaccination. 3 pregnancy and lactating mother. 4 possible physicle urticaria such as cold-induced, pressure induced, heat contact, solar, dermographic, vibratory, aquagenic, cholinergic and drug induced urticaria.

Design outcomes

Primary

MeasureTime frame
Efficacy of Injection Histaglobulin in treatment of ASST positive chronic idiopathic urticariaTimepoint: Baseline First week Second week Third week Fourth week Fifth week Sixth week Seventh week Eighth week—

Secondary

MeasureTime frame
Side effects of Injection HistaglobulinTimepoint: Every week for 10 weeks—

Countries

India

Contacts

Public ContactNipun Ashok Kesarkar

MGMs Medical College and Hospital

ashish7557@gmail.com8237840364

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026